Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:clofarabine
go back to main search page
Accession:CHEBI:681569 term browser browse the term
Definition:A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia.
Synonyms:exact_synonym: 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
 related_synonym: (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol;   2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine;   CAFdA;   Cl-F-Ara-A;   Formula=C10H11ClFN5O3;   InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1;   InChIKey=WDDPHFBMKLOVOX-AYQXTPAHSA-N;   SMILES=Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F;   clofarabina;   clofarabinum
 xref: Beilstein:4882539;   CAS:123318-82-1;   DrugBank:DB00631;   KEGG:D03546
 xref_mesh: MESH:C068329
 xref: PMID:19929004;   Wikipedia:Clofarabine


show annotations for term's descendants           Sort by:
 
clofarabine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Anp32b acidic nuclear phosphoprotein 32 family member B multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of ANP32B protein CTD PMID:20933509 NCBI chr 5:62,070,709...62,094,633
Ensembl chr 5:62,071,346...62,094,633
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of ATM protein CTD PMID:20933509 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [clofarabine co-treated with resveratrol] inhibits the reaction [BCL2L1 mutant form results in increased expression of MCL1 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP3 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP7 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased cleavage of CASP3 protein]; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein]; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein] CTD PMID:25408576 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP3 protein; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP3 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased cleavage of CASP3 protein]; [clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]; [resveratrol co-treated with clofarabine] results in increased cleavage of and results in increased activity of CASP3 protein; [resveratrol co-treated with clofarabine] results in increased expression of CASP3 protein modified form; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] results in increased activity of CASP3 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of CASP3 protein] CTD PMID:20933509 PMID:24239893 PMID:24924397 PMID:25408576 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 multiple interactions ISO [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP7 protein]; [clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]; [resveratrol co-treated with clofarabine] results in increased activity of CASP7 protein; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] results in increased activity of CASP7 protein] CTD PMID:24924397 PMID:25408576 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP9 protein CTD PMID:20933509 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [resveratrol co-treated with clofarabine] results in decreased expression of CCND1 protein CTD PMID:23146690 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cdc25b cell division cycle 25B multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CDC25B protein CTD PMID:20933509 NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[resveratrol co-treated with clofarabine] results in decreased expression of CDKN1A protein]; [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of CDKN1A protein; [resveratrol co-treated with clofarabine] results in decreased expression of CDKN1A protein CTD PMID:20933509 PMID:23146690 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Chek1 checkpoint kinase 1 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK1 protein CTD PMID:20933509 NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
JBrowse link
G Chek2 checkpoint kinase 2 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK2 protein; [clofarabine co-treated with fludarabine] results in increased phosphorylation of CHEK2 protein CTD PMID:20933509 NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO [Clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of H2AX protein CTD PMID:20933509 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
decreases expression
ISO [clofarabine co-treated with resveratrol] inhibits the reaction [BCL2L1 mutant form results in increased expression of MCL1 protein]; [resveratrol co-treated with clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]; [resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein]; clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of CASP3 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein]; resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein] CTD PMID:24924397 PMID:25408576 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [resveratrol co-treated with clofarabine] results in decreased expression of MET protein CTD PMID:23146690 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of MYC protein CTD PMID:20933509 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of PARP1 protein; [resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein; [resveratrol co-treated with clofarabine] results in increased expression of PARP1 protein modified form; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein] CTD PMID:20933509 PMID:24239893 PMID:24924397 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Smc1a structural maintenance of chromosomes 1A multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC1A protein CTD PMID:20933509 NCBI chr  X:21,710,976...21,755,708
Ensembl chr  X:21,711,019...21,755,525
JBrowse link
G Smc3 structural maintenance of chromosomes 3 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC3 protein CTD PMID:20933509 NCBI chr 1:274,310,120...274,352,856
Ensembl chr 1:274,309,758...274,352,854
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [resveratrol co-treated with clofarabine] affects the localization of SP1 protein; [resveratrol co-treated with clofarabine] results in decreased expression of SP1 protein CTD PMID:23146690 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [resveratrol co-treated with clofarabine] affects the localization of TP53 protein modified form; [resveratrol co-treated with clofarabine] results in increased expression of and results in increased activity of TP53 protein modified form; TP53 protein affects the susceptibility to [resveratrol co-treated with clofarabine] CTD PMID:24239893 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of XIAP protein CTD PMID:20933509 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19770
    role 19720
      biological role 19720
        biochemical role 19310
          antimetabolite 8506
            clofarabine 21
Path 2
Term Annotations click to browse term
  CHEBI ontology 19770
    subatomic particle 19768
      composite particle 19768
        hadron 19768
          baryon 19768
            nucleon 19768
              atomic nucleus 19768
                atom 19768
                  main group element atom 19662
                    p-block element atom 19662
                      carbon group element atom 19580
                        carbon atom 19571
                          organic molecular entity 19571
                            heteroorganic entity 19206
                              organochalcogen compound 18951
                                organooxygen compound 18877
                                  carbohydrates and carbohydrate derivatives 12259
                                    carbohydrate 12259
                                      carbohydrate derivative 11889
                                        glycosyl compound 10958
                                          N-glycosyl compound 5480
                                            nucleoside 5342
                                              ribonucleoside 667
                                                purine ribonucleoside 560
                                                  adenosines 543
                                                    clofarabine 21
paths to the root